Market Research Logo

Diagnostic Markets for Women's Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)


Attention: There is an updated edition available for this report.

Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues. However, during the past two decades, there have been major changes in government and private support of women’s health research -- in policies, regulations, and the organization of research efforts. In a recent Institute of Medicine (IOM) report, the Washington DC-based institute found that women’s health research has contributed to significant progress over the past 20 years in lessening the burden of disease and reducing deaths from some conditions for women, while other conditions have seen only moderate change or even little or no change.

This Kalorama Information report, Diagnostic Markets for Women's Health provides insight into this key area of testing. The following tests are among those covered in this report.

  • Pregnancy and Ovulation Tests
  • Bone Density Testing
  • Prenatal Screening
  • Ultrasound
  • Mammography
  • Pap Smears
  • Colposcopy
  • HPV Testing
  • Ovarian Cancer Tests
  • UTI Testing
  • Neonatal Jaundice Testing
  • Auto Immune Disease Testing
  • Cystic Fibrosis Testing

Market size and forecast are provided for these testing markets.

Women make more than 75% of the health care decisions in American households and spend almost two of every three health care dollars. Women also make more than 65% of physician visits, 62% of prescription drug purchases, and 76% of the nursing home population. The life expectancy of women is longer than for men and is climbing steadily due to advancements in medicine. Yet, female health is an area that has much room for improvement both in the development of products and the treatment of diseases.

This report analyzes the current and potential world markets for key diagnostic tests targeted at women’s health. This report generally forecasts future market growth for these tests to 2015. Market segments covered include the world and North American markets. This report also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry.

The report profiles several key companies, including large companies that have made names for themselves in the field, as well as smaller firms with market niches. These companies are involved in developing and marketing over the counter (OTC), point of care (POC) in vitro diagnostic (IVD) tests and screening systems. Some of the companies profiled include

  • GE Healthcare
  • Hologic
  • Perkin Elmer
  • Philips Healthcare
  • Siemens Healthcare
  • Somagen Diagnostics.
Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. The market data are generated into multiple year forecasts for different product segments covered in the report. The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives and researchers.

All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.

For Kalorama's take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information's Key Point Blog at http://kaloramakeypoint.blogspot.com/


Personalized Medicine Takes on Breast Cancer

Personalized medicine and improved diagnostics hold particular promise for improving cancer diagnosis and treatment, where small genetic differences can often impact prognosis and outcomes. Breast cancer is an area where the targeted therapy concept has found real applications and according to healthcare market research publisher Kalorama Information's report, Women's Health Diagnostic Testing Markets, patients are already beginning to benefit from tests that help tailor treatment of the more than 200,000 cases diagnosed annually.

"Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues," said Bruce Carlson, publisher of Kalorama Information. "That's changing, as campaigns to increase breast cancer awareness have resulted in more funding, which in turn has meant better screening, treatments and survival rates for women."

Meanwhile, the revolution in bioinformatics has allowed scientists to mine genetic information to derive new and hopefully better markers for breast cancer, as well as for cardiac disease, diabetes and autoimmune disorders. This has contributed to advances in immunoassays and nucleic acid tests.

Kalorama notes that today physicians routinely run tests to determine if a patient has human epidermal growth factor receptor-2 (HER2) positive breast cancer, which is more aggressive but responds better to targeted treatment. HER2-positive patients must undergo a different treatment regimen than those with HER2-negative breast cancer.

Clarient, which was purchased by GE Healthcare in 2010, launched a tool to aid physicians with prognosis and decision-making in treating breast cancer patients beyond the HER2 question. The Clarient Insight Dx Breast Cancer Profile uses a combination of pathology risk factors and molecular markers to categorize patients with early-stage, hormone-receptor-positive breast cancer as either at high or low risk of recurrence.

"A $500 test to determine if a breast cancer patient will benefit or not from a specific chemotherapy drug seems a small price to pay when treatment that will cost $25,000 to $80,000," says Carlson.

Women's Health Diagnostic Testing Markets, details and analyzes the current and potential world markets for key diagnostic tests targeted at women's health. Pregnancy and ovulation testing, bone density testing, pap smears, mammography, and ultrasound are among the tests that target female health. This report also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry.

CHAPTER ONE: EXECUTIVE SUMMARY
1.1 Women’s Health in Focus
1.2 Diagnostics Moving Forward
1.2.1 Advancing Female Health
1.2.2 Studying the Most Relevant Groups
1.2.3 Translating Research into Practice
1.3 Key Issues Involving Women’s Health
1.4 Market Picture
1.4.1 Overall Trends
1.4.2 Key Diagnostic Forecasts
1.4.3 Methodology
CHAPTER TWO: INTRODUCTION
2.1 Perspective on Women’s Health
2.2 Key Differences between the Sexes
2.2.1 Autoimmune Disease
2.2.2 Cancer
2.2.3 Musculoskeletal Health
2.2.4 Birth Defects
2.2.5 Urinary Tract Infections
2.3 Key Leading Causes of Death in Females
2.4 Demographics
2.4.1 What Claims Women’s Lives
2.5 Key Trends and Issues in Women’s Diagnostics
2.5.1 Understanding the Molecular Basis of Disease
2.5.2 Managing Cancer Disease and Costs
2.5.3 Ultrasound and Mammography Use Grows
CHAPTER THREE: PREGNANCY AND OVULATION
3.1 Perspective on Testing
3.1.1 Digital Testing
3.2 OTC Test Market Forecast
3.3 Church & Dwight Co. Inc.
3.4 Inverness Medical Innovations
3.5 Siemens Healthcare Diagnostics
CHAPTER FOUR: BONE DENSITY TESTING
4.1 Alarming Rise of Osteoporosis
4.1.1 Bone Mineral Density
4.1.2 Refining Diagnosis
4.2 Bone Densitometer Market Forecast
4.3 GE Healthcare
4.4 Hologic
4.5 Osteometer MediTech
CHAPTER FIVE: PRENATAL SCREENING
5.1 Perspective
5.1.1 Advances
5.2 Value of Informed Choice
5.3 The Impact of Prenatal Genetic Testing
5.4 DNA Assay Market Forecast
5.5 PerkinElmer
5.6 Quest Diagnostics
5.7 Sequenom
CHAPTER SIX: ULTRASOUND
6.1 History and Perspective
6.1.1 Advances in Technology
6.2 Obstetrics and Gynecology
6.3 Breast Imaging
6.4 Market Forecasts
6.4.1 Ob/Gyn Market
6.4.2 Breast Imaging
6.5 Analogic
6.6 Philips Healthcare
6.7 Siemens Healthcare
CHAPTER SEVEN: MAMMOGRAPHY
7.1 Perspective
7.1.1 Routine Screening
7.2 Transitioning to Digital
7.3 Computer-Aided Detection
7.4 Market Forecasts
7.4.1 Mammography Systems
7.4.2 CAD
7.5 Carestream Health
7.6 FujiFilm Medical Systems USA
7.7 GE Healthcare
7.8 Hologic
CHAPTER EIGHT: PAP SMEARS
8.1 Testing for Cervical Cancer
8.1.1 Types of Screening
8.2 Cervical Cancer Shot
8.3 A Market Need
8.3.1 IVD Market Forecasts
8.4 Becton Dickinson
8.5 Hologic
8.6 Innogenetics NV
CHAPTER NINE: COLPOSCOPY
9.1 Biopsy Procedure
9.1.1 Pap Smear Concerns
9.1.2 Routine Use
9.2 Markets for Colposcopy Systems
9.2.1 Primary and Secondary Screening
9.3 CooperSurgical 95 Corporate Dr. Trumbull, CT 06611
9.4 Guided Therapeutics
9.5 NeoDiagnostix
CHAPTER TEN: HPV TESTING
10.1 HPV Defined
10.1.1 High Risk Types
10.1.2 Relationship to Cervical Cancer
10.2 Vaccine Issues
10.3 Strong Market Expected
10.3.1 IVD Market Forecasts
10.4 Abbott Diagnostics
10.5 Hologic
10.6 Qiagen Benelux BV
CHAPTER ELEVEN: OVARIAN CANCER
11.1 Types of Ovarian Cancer
11.2 Different Diagnostic Techniques
11.3 Tumor Markers and Antigens
11.4 CA-125 Market Forecast
11.5 Abbott Diagnostics
11.6 Fujirebio Diagnostics
CHAPTER TWELVE: URINARY TRACT INFECTIONS
12.1 Leading Cause of Morbidity and Death
12.1.1 Impact of Hospital Acquired Infections
12.1.2 Impact on Women
12.2 E. coli the Key Culprit
12.3 Market Forecasts Molecular Testing
12.4 Amerifit
12.5 Liofilchem
12.6 Rheonix
12.7 Somagen Diagnostics
CHAPTER THIRTEEN: NEONATAL JAUNDICE
13.1 Issues Involving Bilirubin
13.2 Two Factors in Neonates
13.3 Risk Factors
13.4 Autism Link
13.5 Market Forecasts Bilirubin Testing
13.6 Instrumentation Laboratory
13.7 Nova Biomedical
13.8 Siemens Healthcare Diagnostics
13.9 Wako Diagnostics
CHAPTER FOURTEEN: AUTOIMMUNE DISEASE
14.1 Genetic Factors
14.2 Low-Level Autoimmunity
14.3 Impact on Females
14.4 Types of Autoimmune Disease
14.5 IVD Market Forecasts
14.6 Bio-Rad Laboratories
14.7 Kronus
14.8 Phadia
14.9 XDx
CHAPTER FIFTEEN: CYSTIC FIBROSIS
15.1 Affecting the Entire Body
15.2 Reduced Life Expectancy
15.3 Genetics
15.4 Chronic Infections
15.5 Market Forecast Genetic Testing
15.6 AutoGenomics
15.7 GenMark Diagnostics
15.8 Gen-Probe
15.9 Luminex
15.10 Sequenom

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report